Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 P
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that … RNA therapies for genetic eye diseases and our proprietary RNA-editing platform technology.” “I first met Daniel more than a …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNAediting technology platform, today reported its financial …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ® RNAediting technology platform, today reported its financial …
… company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a … event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline …
… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi